Targeted radiation therapy for high-risk prostate cancer
Official title: PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-10440533 · Data updated 2026-11-12
This study is exploring a new way to treat high-risk prostate cancer by using special imaging techniques to find cancer spots more accurately, so patients can receive targeted radiation therapy in just five sessions, which aims to reduce side effects and improve treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $155,093 |
| NIH project number | 5R01CA249615-03 |
| Project ID | NIH-10440533 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with high-risk localized prostate cancer who are seeking advanced treatment options.
✕Less likely to help
Patients with low-risk prostate cancer or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research investigates a new approach to treating high-risk prostate cancer using advanced imaging and radiation techniques. It combines PSMA PET and MRI to accurately identify cancerous areas within the prostate, allowing for a more precise delivery of radiation therapy. The treatment is designed to be completed in just five sessions, minimizing toxicity while aiming to improve outcomes for patients with aggressive cancer. By utilizing real-time adaptive planning during radiation delivery, the therapy can be tailored to the patient's specific needs.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and reduce recurrence in patients with high-risk prostate cancer.
How similar studies have gone: Other research has shown promising results using similar imaging and radiation techniques, indicating potential for success in this novel approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Formenti, Silvia C. — Weill Medical Coll of Cornell Univ
- Study coordinator: Formenti, Silvia C.
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Resistance to AR-Targeted Therapy in High-Risk Prostate Cancer
Researchers are studying why some high-risk prostate cancers stop responding to AR pathway inhibitors and trying new strategies to improve outcomes for men with aggressive, localized disease.
-
Tumor environment players in advanced prostate cancer spread
Researchers are studying how the tissue around prostate tumors helps cancer spread, in men with high-risk disease.
-
Integrated genomic and AI pathology biomarkers to guide high-risk prostate cancer treatment
A prostate cancer research project tests how genomic and AI-based pathology tools can help tailor who should receive added ARSI therapy with standard radiotherapy and hormone treatment.
-
Reducing prostate cancer radiotherapy toxicity through genes and technology
A study to find genetic clues that predict who will have side effects from prostate cancer radiotherapy and to use new tools to reduce those risks.
-
MRI and blood tests to predict prostate cancer outcomes after radiation
This project uses repeated MRI scans and blood-based tumor markers to find early signs that predict how men with intermediate or high-risk prostate cancer do after radiation and hormone therapy.
-
Mitochondrial changes in high-risk prostate cancer
This project looks at changes in mitochondrial DNA and cell energy systems in men, especially African American men, with high‑risk prostate cancer to find markers that predict who will develop aggressive disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.